Axsome Therapeutics Inc. priced a public offering of its common stock to raise about $174 million in gross proceeds.
The New York-based biopharmaceutical company is offering 2 million shares at $87 apiece. Underwriters will also receive an option to buy up to an additional 300,000 shares.
Net proceeds from the offering, excluding the underwriters' option, are expected to be about $162.2 million.
Axsome intends to use the proceeds from this offering to fund the development of its drug candidates, clinical programs and for general corporate purposes.
The offering is scheduled to close Dec. 23.
SVB Leerink is acting as lead book-running manager for the offering. Morgan Stanley is acting as joint book-running manager for the offering.
Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc., SunTrust Robinson Humphrey Inc. and William Blair & Co. LLC are acting as co-lead managers for the offering. BTIG LLC and H.C. Wainwright & Co. are acting as co-managers for the offering.